Shira Eytan, MD, FACE

January 20, 2025

Panelists discuss how early identification of Type 1 diabetes through screening programs, combined with emerging therapies like teplizumab, offers new opportunities for intervention and improved patient outcomes in at-risk populations.

January 20, 2025

Panelists discuss how patient selection for teplizumab therapy requires screening for specific autoantibodies and stages of Type 1 diabetes, followed by a standardized 14-day outpatient infusion protocol with careful monitoring for side effects.

January 20, 2025

Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.

January 20, 2025

Panelists discuss how islet autoantibody testing serves as a critical screening tool for identifying Type 1 diabetes risk, with tests detecting antibodies against insulin, GAD65, IA-2, and ZnT8 proteins being the most clinically validated markers.

January 20, 2025

Panelists discuss how patient selection for teplizumab therapy requires careful screening for autoantibody positivity and preserved C-peptide function, followed by a 14-day outpatient infusion process that needs close monitoring for cytokine release syndrome and other potential adverse effects.

January 20, 2025

Panelists discuss how teplizumab demonstrated efficacy in clinical trials by delaying type 1 diabetes onset in high-risk patients.

January 20, 2025

Panelists discuss how teplizumab binds to T cells and modifies their function to preserve beta cell function, potentially delaying type 1 diabetes onset in at-risk individuals by an average of 2-3 years.

January 20, 2025

Panelists discuss how screening for autoantibodies can help identify individuals at risk for type 1 diabetes before symptoms develop, enabling earlier intervention and potentially delaying disease onset.

December 23, 2024

Panelists discuss how delaying intervention during Stage 2 Type 1 diabetes increases the risk of diabetic ketoacidosis and complications at diagnosis, while also potentially accelerating beta cell destruction and reducing the window for preservation therapies.

December 23, 2024

Panelists discuss how Type 1 diabetes progresses through distinct stages, from initial autoimmunity with normal blood glucose (Stage 1), to dysglycemia without symptoms (Stage 2), to clinical diagnosis with symptoms (Stage 3), marking critical intervention points for treatment and management.